|
By HCat at 2007-02-27 21:35
|
|
   GlaxoSmithKline has initiated a phase III trial of Tykerbterm in squamous cell carcinomaterm of the head and neck (SCCHN). Phase I results of lapatinib in SCCHN were recently reported at the European Society for Therapeutic Radiology and Oncology (ESTRO). The phase III trial design is based on results in papers from the New England Journal of Medicine found here and here, where researchers investigated post-operative treatment of high-risk SCCHN patients. This trial will compare the effectiveness of oral lapatinib versus placebo given to high-risks patients following surgery.
|
|
read more | 1533 reads
|
|
By HCat at 2007-02-14 02:20
|
|
   Marshall R. Posner, MD, medical director of the Head and Neck Oncology Program at the Dana-Farber Cancer Institute in Boston reported at the 2006 annual meeting of the American Society of Clinical Oncology (ASCO) on the randomized Phase III TAX 324 Study Group. 501 patients with locally advanced squamous cell carcinomaterm of the head and neck (SCCHN) (oral cavity, oropharynx, larynx and hypopharynx) were the focus of the study.
Â
   In the study, patients receiving docetaxel in combination with cisplatin and 5-FUterm as induction (neoadjuvant) therapy, followed by chemoradiotherapy and surgery were compared to those not receiving docetaxel. The results showed an impressive 70.6 months median overall survival in patients who took docetaxel compared to 30.1 months for those not receiving docetaxel in their treatment. There was a 30% reduction in mortality rate for those patients receiving docetaxel. There was an absolute three-year survival improvement of 14% in the docetaxel group as well. Progression-free survival (PFS) was also significantly greater with the docetaxel regimen with two-year PFS at 53% compared to 42%.
|
|
read more | 3910 reads
|
Register
